On August 13, 2026, Neurocrine Biosciences Inc NBIX shares fell 3.6% to a current price of $150.82. This decline continues a trend of decreased prices, with the stock down 5.6% over the past week and 13.4% over the last month. The 52-week range for NBIX spans from a low of $122.14 to a high of $186.12.
- GF Value™ verdict: NBIX is currently priced at $150.82, which is 23.0% below the GF Value™ estimate of $195.85, indicating it is undervalued.
- GF Score™: NBIX has a strong GF Score™ of 94/100, reflecting its robust financial health and growth potential.
- Most notable signal: Insider activity shows that insiders sold $61.9 million worth of shares in the last three months, with no purchases reported.
Is NBIX Overvalued or Undervalued?
The current valuation of Neurocrine Biosciences Inc presents an intriguing case for investors. With a GF Value™ of $195.85 compared to the trading price of $150.82, the stock appears to be undervalued by 23.0%. This margin of safety provides a potential opportunity for investors looking for growth, as the current price is significantly lower than what GuruFocus estimates it should be trading at based on various financial metrics, including historical performance and future earnings expectations. The GF Valuation label categorizes NBIX as "Modestly Undervalued," suggesting reasonable growth potential ahead.
However, it is crucial to consider the risks associated with this valuation. The absence of insider buying amid significant selling activity may indicate a lack of confidence from those closest to the company. While the undervaluation presents an opportunity, investors should be cautious and examine the underlying reasons for the stock’s recent performance before making any decisions.
How Does NBIX's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 22.1x | 42.8x |
| Forward P/E | 21.3x | N/A |
Currently, Neurocrine Biosciences Inc has a trailing P/E ratio of 22.1x, which is significantly below its 5-year median P/E of 42.8x, indicating that the stock is trading at nearly 48% lower than its historical valuation. This P/E analysis aligns with the GF Value™ verdict, supporting the case that NBIX is undervalued at its current price. The forward P/E of 21.3x suggests that analysts expect modest earnings growth moving forward, which could further enhance the attractiveness of the stock if the company meets or exceeds these expectations.
What Does NBIX's GF Score™ Tell Us?
The GF Score™ evaluates a company’s financial strength, profitability, growth, valuation, and momentum to provide a comprehensive snapshot of its overall health and potential for long-term success. Neurocrine Biosciences Inc’s GF Score™ of 94/100 reflects strong performance across multiple dimensions, with its highest sub-rank being Growth, rated at 10/10, and the lowest being Momentum, rated at 6/10.
| Metric | Rating |
|---|---|
| GF Score™ | 94/100 |
| Financial Strength | 9/10 |
| Profitability | 8/10 |
| Growth | 10/10 |
| Valuation | 8/10 |
| Momentum | 6/10 |
Overall, Neurocrine’s strong GF Score™ indicates a solid financial foundation and exceptional growth prospects. The high ratings in Financial Strength and Growth suggest that the company is well-positioned to capitalize on its opportunities. However, the lower Momentum score indicates that the stock may be experiencing some headwinds in the short term, which could be a factor in recent price declines.
What Are Gurus and Insiders Doing with NBIX?
Currently, 11 gurus hold shares of Neurocrine Biosciences Inc, with 6 adding to their positions while another 6 have trimmed their holdings in recent quarters. This mixed activity among guru investors indicates a divided sentiment regarding the stock's prospects moving forward.
On the insider front, significant selling activity totaling $61.9 million in the last three months raises concerns about the management's confidence in the company's short-term performance. The lack of any insider buying during this period could be interpreted as a bearish signal, suggesting that insiders may not see immediate catalysts for price appreciation.
What This Means for Investors
Based on the GF Value™ analysis, Neurocrine Biosciences Inc appears to be undervalued at its current price of $150.82 when compared to the estimated fair value of $195.85. While there is a potential opportunity for investors, the selling pressure from insiders and the recent performance trends warrant careful consideration. Investors should weigh these factors against the company's strong GF Score™ and growth potential before making any decisions.
For further insights into Neurocrine Biosciences Inc NBIX, visit the Neurocrine Biosciences Inc (NBIX) stock page for detailed analysis, or explore the GF Value™ page for more information on valuation metrics.
Frequently Asked Questions
What is NBIX's GF Score™?
NBIX has a GF Score™ of 94/100, indicating a strong overall performance across various financial metrics.
Is NBIX overvalued or undervalued?
According to the GF Value™ estimate, NBIX is currently undervalued, with a 23.0% margin compared to its fair value of $195.85.
What is NBIX's P/E ratio?
NBIX has a trailing P/E ratio of 22.1x, which is significantly below its 5-year median P/E of 42.8x, indicating it is trading at a lower valuation than in the past.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
